IGC (IGC Pharma) Ending Cash Position: $0.21 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IGC IGC Pharma Inc IGC
29 GF Score
Price $0.27
GF Value $0.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Ending Cash Position?

IGC Pharma IGC +1.05% 29 Ending Cash Position is $0.21 Mil as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

IGC Pharma's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.21 Mil.

IGC Pharma's quarterly Ending Cash Position declined from Sep. 2025 ($1.11 Mil) to Dec. 2025 ($0.90 Mil) and declined from Dec. 2025 ($0.90 Mil) to Mar. 2026 ($0.21 Mil).

IGC Pharma's annual Ending Cash Position declined from Mar. 2023 ($3.20 Mil) to Mar. 2024 ($1.20 Mil) and declined from Mar. 2024 ($1.20 Mil) to Mar. 2025 ($0.47 Mil).

IGC Pharma Ending Cash Position Related Terms

IGC Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Ending Cash Position Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.55 10.46 3.20 1.20 0.47

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.45 1.11 0.90 0.21
IGC
29GF Score
IGC Pharma Inc IGC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

IGC Pharma's Ending Cash Position for the fiscal year that ended in Mar. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.198+-0.728
=0.47

IGC Pharma's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.9+-0.693
=0.21

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.21 Mil mean?
IGC Pharma (IGC) has a Ending Cash Position of $0.21 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on IGC Pharma and its competitors.
Is IGC Pharma's Ending Cash Position too high?
IGC Pharma's current Ending Cash Position is $0.21 Mil. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Ending Cash Position compare to SER and NRSN?
IGC Pharma's Ending Cash Position of $0.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on IGC Pharma and its competitors. IGC Pharma's current Ending Cash Position is $0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 12.5% above its estimated fair value. The current Ending Cash Position is $0.21 Mil. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For IGC Pharma (IGC), the current Ending Cash Position is $0.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.27 is trading 12.5% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

  • Ending Cash Position: $0.21 Mil
  • GF Value™: $0.24 vs. price of $0.27 (12.5% above fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score

Get the complete analysis for IGC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price
$0.24
GF Value